Please assess the completion status of the following clinical trial:

Trial Title: A Pilot Study of Radiation-Immune Cell Combination Therapy in Cervical Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients must have signed an approved informed consent and authorization permitting release of personal health information.~2. Age 18-75 years~3. Pathologically proven recurrent or persistent cervical cancer patients resistant to conventional palliative chemotherapy or radiation therapy~   1. Persistent tumor more than 1cm after initial chemoradiation or radiation therapy~  2. Persistent tumor more than 1cm after chemoradiation, radiation or chemotherapy in recurrent cervical cancer~  3. Metastatic cervical cancer to lung resistant to conventional chemotherapy~4. ECOG performance status 0, 1, 2.~5. Expected survival more than 3 months~6. Patients must have adequate:~   Hematologic function: ANC ≥ 1,500/mcl, Hemoglobin \>10g/dL, platelets ≥ 100,000/mcl Renal function: creatinine ≤ 1.5 x ULN Hepatic function: AST, ALT ≤ 1.5 x ULN,~7. More than 3 weeks from the last day of previous chemotherapy or radiation~Exclusion Criteria:~1. Patients with immune disease or auto-immune disease (ex. rheumatoid arthritis, SLE, immune vasculitis, IDDM)~2. Immune deficiency disease~3. Cancers other than cervical cancer within 5 years~4. Acute myocardial infarction, uncontrolled hypertension~5. Severe allergic disease~6. Severe psychotic disease~7. Those who can be a candidate for curative surgery

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Low dose radiation, Immune cell therapy (Type: EXPERIMENTAL): Combination treatment of low-dose radiation 20cGy every 3 weeks three times and autologous immune cell therapy 2 consecutive weeks 3 times every 3 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).